
-
Novo Nordisk NYSE:NVO Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Location: Novo Alle 1, Bagsvaerd, 2880, Denmark | Website: https://www.novonordisk.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
362.9B
Cash
41.55B
Avg Qtr Burn
N/A
Short % of Float
0.79%
Insider Ownership
0.01%
Institutional Own.
9.84%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Alhemo® (concizumab) Details Hemophilia, Blood disorder | Approved Quarterly sales | |
Once-weekly basal insulin icodec Details Diabetes mellitus , Type 1 diabetes | BLA Resubmission | |
Phase 3 Data readout | ||
CagriSema Details Obesity, Type 2 diabetes | Phase 3 Data readout | |
Etavopivat (FT-4202) (PKR activator) Details Sickle cell disease | Phase 2/3 Update | |
FT-7051 (CBP/P300 inhibitor) Details Castration-resistant prostate cancer | Failed Discontinued |